Alnylam Pharmaceuticals Inc.

In News

BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN

MSN - Jul 04, 2025

Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com

Investing.com - Jul 07, 2025

Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra

JD Supra - Jun 09, 2025

Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo Finance

Yahoo Finance - May 13, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $333.00 at Wells Fargo & Company - MarketBeat

MarketBeat - Jul 03, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Business Wire

Business Wire - Mar 20, 2025

Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive

BioPharma Dive - Mar 20, 2025

Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus

GuruFocus - Jul 07, 2025

Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab - Law360

Law360 - Jul 02, 2025

CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com

IPWatchdog.com - Jun 04, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire

Business Wire - Jun 18, 2025

Alnylam Pharmaceuticals stock hits all-time high at 326.12 USD - Investing.com

Investing.com - Jun 30, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.